New combo pill targets tummy troubles: pain and gas relief in one
NCT ID NCT05175131
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tested a fixed-dose combination of Mebeverine (a muscle relaxant) and Simethicone (a gas reducer) against each drug alone in 465 adults with functional bowel disorders causing abdominal pain and bloating. The goal was to see if the combo pill better reduces pain and bloating after 4 weeks. Participants rated their symptoms daily on a 0-10 scale.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Mebeverine + Simethicone fixed-dose combination
What this could lead to
If successful, this combination pill could offer a more convenient and effective way to relieve both abdominal pain and bloating in people with functional bowel disorders.
What could go wrong
This is a completed Phase 3 trial, but results are not yet published. The combination may not prove significantly better than taking either drug alone, and individual responses vary.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FUNCTIONAL BOWEL DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Null Research Facilities
Moscow, Russia